NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NAMS NEWAMSTERDAM PHARMA CO NV

盘后交易 08-13 19:52:43 EDT

25.76

+0.76

+3.04%

盘后25.72

-0.04-0.16%

19:20 EDT

最高25.80	最低24.95	成交量57.99万
今开25.19	昨收25.00	日振幅3.40%
总市值29.01亿	流通市值14.19亿	总股本1.13亿
成交额1,477万	换手率1.05%	流通股本5,507万
市净率3.73	ROE-28.43%	每股收益-1.55
52周最高27.29	52周最低14.06	市盈率-16.67
股息0.00	股息收益率0.00	ROA-17.12%

北京优虎网络科技有限公司

{"stockData":{"symbol":"NAMS","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV","latestPrice":25.76,"timestamp":1755115200000,"preClose":25,"halted":0,"volume":579883,"hourTrading":{"tag":"盘后","latestPrice":25.72,"preClose":25.76,"latestTime":"19:20 EDT","volume":52961,"amount":1364336.1592279999,"timestamp":1755127235627},"delay":0,"floatShares":55074561,"shares":112628458,"eps":-1.545475,"marketStatus":"盘后交易","change":0.76,"latestTime":"08-13 19:52:43 EDT","open":25.19,"high":25.8,"low":24.95,"amount":14772618.00511,"amplitude":0.034,"askPrice":28,"askSize":4,"bidPrice":23.57,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-1.545475,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1755129600000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":25,"preHourTrading":{"tag":"盘前","latestPrice":25.4,"preClose":25,"latestTime":"09:24 EDT","volume":407,"amount":10421.27977,"timestamp":1755091481884},"postHourTrading":{"tag":"盘后","latestPrice":25.72,"preClose":25.76,"latestTime":"19:20 EDT","volume":52961,"amount":1364336.1592279999,"timestamp":1755127235627},"volumeRatio":0.517503,"impliedVol":0.7678,"impliedVolPercentile":0.508},"requestUrl":"/m/hq/s/NAMS","defaultTab":"news","newsList":[{"id":"2558873669","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大跌6.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558873669","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558873669?lang=zh_cn&edition=full","pubTime":"2025-08-11 21:35","pubTimestamp":1754919314,"startTime":"0","endTime":"0","summary":"北京时间2025年08月11日21时35分，Newamsterdam Pharma Company N.V.股票出现波动，股价快速下跌6.08%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.15%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508112135149740e4ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508112135149740e4ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2557578224","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大涨5.05%报24.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557578224","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557578224?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:42","pubTimestamp":1754660556,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时42分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速上涨5.05%。截至发稿，该股报24.12美元/股，成交量2.2588万股，换手率0.02%，振幅3.27%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.32%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821423694d7cd93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025080821423694d7cd93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2557309455","title":"Newamsterdam Pharma Company N.V.盘中异动 下午盘大幅上涨5.06%报22.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557309455","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557309455?lang=zh_cn&edition=full","pubTime":"2025-08-07 01:29","pubTimestamp":1754501387,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日01时29分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速拉升5.06%。截至发稿，该股报22.83美元/股，成交量46.226万股，换手率0.41%，振幅7.21%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.31%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807012948a6d704cb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250807012948a6d704cb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2555040941","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘快速下挫5.27%报21.58美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2555040941","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2555040941?lang=zh_cn&edition=full","pubTime":"2025-07-30 22:05","pubTimestamp":1753884300,"startTime":"0","endTime":"0","summary":"北京时间2025年07月30日22时05分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速跳水5.27%。截至发稿，该股报21.58美元/股，成交量15.1522万股，换手率0.13%，振幅8.96%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.51%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073022050094c404c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025073022050094c404c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2552435221","title":"Newamsterdam Pharma Company N.V.盘中异动 大幅上涨5.02%报21.97美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552435221","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552435221?lang=zh_cn&edition=full","pubTime":"2025-07-18 01:37","pubTimestamp":1752773827,"startTime":"0","endTime":"0","summary":"北京时间2025年07月18日01时37分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速拉升5.02%。截至发稿，该股报21.97美元/股，成交量27.0311万股，换手率0.24%，振幅6.63%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.05%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718013707a4519631&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718013707a4519631&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2551194086","title":"Newamsterdam Pharma Company N.V.盘中异动 大幅下跌5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194086","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551194086?lang=zh_cn&edition=full","pubTime":"2025-07-16 03:55","pubTimestamp":1752609301,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日03时55分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速下挫5.00%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为1.15%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716035502a44cfbbc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716035502a44cfbbc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2551973182","title":"Newamsterdam Pharma Company N.V.盘中异动 急速拉升5.20%报22.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551973182","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551973182?lang=zh_cn&edition=full","pubTime":"2025-07-14 22:36","pubTimestamp":1752503769,"startTime":"0","endTime":"0","summary":"北京时间2025年07月14日22时36分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速拉升5.20%。截至发稿，该股报22.66美元/股，成交量34.7892万股，换手率0.31%，振幅7.37%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为1.06%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714223609a44a3913&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714223609a44a3913&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2550656300","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大涨5.19%报21.06美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550656300","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550656300?lang=zh_cn&edition=full","pubTime":"2025-07-09 21:48","pubTimestamp":1752068928,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日21时48分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速拉升5.19%。截至发稿，该股报21.06美元/股，成交量5.0038万股，换手率0.04%，振幅3.97%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为1.10%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214848953c3856&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709214848953c3856&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2543086603","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大跌5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2543086603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543086603?lang=zh_cn&edition=full","pubTime":"2025-06-16 22:06","pubTimestamp":1750082798,"startTime":"0","endTime":"0","summary":"北京时间2025年06月16日22时06分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速跳水5.20%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为0.14%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506162206389781f58e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506162206389781f58e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2542553846","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542553846","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542553846?lang=zh_cn&edition=full","pubTime":"2025-06-11 22:08","pubTimestamp":1749650914,"startTime":"0","endTime":"0","summary":"北京时间2025年06月11日22时08分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速下挫5.08%。截至发稿，该股报20.73美元/股，成交量15.207万股，换手率0.14%，振幅5.27%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.05%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611220834977b105f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250611220834977b105f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2542343122","title":"NewAmsterdam Pharma Co(NAMS.US)获Stifel首次覆盖，给予买入评级, 目标价44.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2542343122","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542343122?lang=zh_cn&edition=full","pubTime":"2025-06-10 22:42","pubTimestamp":1749566558,"startTime":"0","endTime":"0","summary":"NewAmsterdam Pharma Co(NAMS.US)获Stifel首次覆盖，给予买入评级, 目标价44.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/06/10224250989072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["NAMS"],"gpt_icon":0},{"id":"2542086348","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大涨5.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542086348","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542086348?lang=zh_cn&edition=full","pubTime":"2025-06-10 21:33","pubTimestamp":1749562388,"startTime":"0","endTime":"0","summary":"北京时间2025年06月10日21时33分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速拉升5.16%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.68%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610213308a7023944&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250610213308a7023944&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2542387066","title":"Newamsterdam Pharma Company N.V.盘中异动 大幅拉升6.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2542387066","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2542387066?lang=zh_cn&edition=full","pubTime":"2025-06-09 21:31","pubTimestamp":1749475883,"startTime":"0","endTime":"0","summary":"北京时间2025年06月09日21时31分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速拉升6.68%。截至发稿，该股报21.49美元/股，成交量9.1059万股，换手率0.08%，振幅2.41%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.45%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609213123a4a07a95&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250609213123a4a07a95&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2541060529","title":"Newamsterdam Pharma Company N.V.盘中异动 急速上涨5.22%报19.67美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2541060529","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2541060529?lang=zh_cn&edition=full","pubTime":"2025-06-05 00:10","pubTimestamp":1749053413,"startTime":"0","endTime":"0","summary":"北京时间2025年06月05日00时10分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速上涨5.22%。截至发稿，该股报19.67美元/股，成交量25.1586万股，换手率0.22%，振幅4.60%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为0.75%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605001013a49a211e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250605001013a49a211e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2540771389","title":"Newamsterdam Pharma Company N.V.盘中异动 急速拉升5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2540771389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2540771389?lang=zh_cn&edition=full","pubTime":"2025-06-03 03:52","pubTimestamp":1748893936,"startTime":"0","endTime":"0","summary":"北京时间2025年06月03日03时52分，Newamsterdam Pharma Company N.V.股票出现异动，股价快速上涨5.02%。截至发稿，该股报19.02美元/股，成交量62.0186万股，换手率0.55%，振幅6.75%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为1.43%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603035217a6f7776d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250603035217a6f7776d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2537497953","title":"Newamsterdam Pharma Company N.V.盘中异动 下午盘快速下挫5.01%报18.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537497953","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537497953?lang=zh_cn&edition=full","pubTime":"2025-05-22 02:00","pubTimestamp":1747850458,"startTime":"0","endTime":"0","summary":"北京时间2025年05月22日02时00分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速下跌5.01%。截至发稿，该股报18.38美元/股，成交量18.8148万股，换手率0.17%，振幅5.27%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为1.23%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。其产品 obicetrapib 是下一代口服低剂量 CETP 抑制剂，为了克服当前 LDL-C 降低治疗的局限性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052202005894fe33f9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052202005894fe33f9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","NAMS"],"gpt_icon":0},{"id":"2534274726","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘急速拉升5.28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534274726","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534274726?lang=zh_cn&edition=full","pubTime":"2025-05-12 22:14","pubTimestamp":1747059287,"startTime":"0","endTime":"0","summary":"北京时间2025年05月12日22时14分，Newamsterdam Pharma Company N.V.股票出现波动，股价快速拉升5.28%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体涨幅为2.68%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。消息层面，截至22时14分，《Needham：维持NewAmsterdam Pharma Co评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。》资讯为影响Newamsterdam Pharma Company N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051222144794f48a74&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051222144794f48a74&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2534532824","title":"Newamsterdam Pharma Company N.V.盘中异动 股价大跌5.19%报18.27美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2534532824","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534532824?lang=zh_cn&edition=full","pubTime":"2025-05-10 00:54","pubTimestamp":1746809672,"startTime":"0","endTime":"0","summary":"北京时间2025年05月10日00时54分，Newamsterdam Pharma Company N.V.股票出现波动，股价急速下跌5.19%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为3.29%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。消息层面，截至00时54分，《Needham：维持NewAmsterdam Pharma Co评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。》资讯为影响Newamsterdam Pharma Company N.V.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510005432aa2c8985&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250510005432aa2c8985&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0},{"id":"2534168443","title":"Needham：维持NewAmsterdam Pharma Co评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2534168443","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534168443?lang=zh_cn&edition=full","pubTime":"2025-05-09 03:02","pubTimestamp":1746730963,"startTime":"0","endTime":"0","summary":"Needham：维持NewAmsterdam Pharma Co(NAMS.US)评级，由买入调整至买入评级, 目标价由42.00美元调整至40.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090305439753886a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202505090305439753886a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS"],"gpt_icon":0},{"id":"2533493137","title":"Newamsterdam Pharma Company N.V.盘中异动 早盘股价大跌5.79%报17.83美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2533493137","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2533493137?lang=zh_cn&edition=full","pubTime":"2025-05-08 21:56","pubTimestamp":1746712581,"startTime":"0","endTime":"0","summary":"北京时间2025年05月08日21时56分，Newamsterdam Pharma Company N.V.股票出现异动，股价急速下挫5.79%。Newamsterdam Pharma Company N.V.股票所在的生物技术行业中，整体跌幅为2.93%。Newamsterdam Pharma Company N.V.公司简介：NewAmsterdam Pharma Co NV 是一家处于后研发阶段的生物制药公司，其使命是改善代谢性疾病患者的护理，这些疾病目前批准的疗法尚未充分或耐受性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050821562197534f17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050821562197534f17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NAMS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.1505},{"period":"1month","weight":0.1606},{"period":"3month","weight":0.3333},{"period":"6month","weight":0.2887},{"period":"1year","weight":0.4671},{"period":"ytd","weight":-0.0272}],"compareEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":0.0306},{"period":"3month","weight":0.0938},{"period":"6month","weight":0.0541},{"period":"1year","weight":0.2052},{"period":"ytd","weight":0.0966}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NewAmsterdam Pharma Company N.V.于2019年10月17日以NewAmsterdam Pharma B.V.的名义根据荷兰法律成立为一家私人有限责任公司。NewAmsterdam Pharma于2021年10月更名为NewAmsterdam Pharma Holding B.V.。他们是一家临床阶段的生物制药公司，为心血管疾病（CVD）高危患者开发口服非他汀类药物，这些患者的低密度脂蛋白胆固醇（LDL-C或LDL）残留升高，而现有疗法对这些患者不够有效或耐受良好。作为他汀类药物的辅助药物，一种有效的、具有成本效益的和方便的低密度脂蛋白降低疗法存在着巨大的未满足需求。他汀类药物是目前高胆固醇高危CVD患者的标准护理。他们的主要候选产品obicetrapib是一种下一代口服低剂量胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行四项3期和2b期临床试验，作为单一疗法和依折麦布联合疗法，用于降低LDL-C和预防主要心血管不良事件（“MACE”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.233023},{"month":2,"riseRate":0.25,"avgChangeRate":0.01095},{"month":3,"riseRate":0.6,"avgChangeRate":-0.001317},{"month":4,"riseRate":0.4,"avgChangeRate":-0.013613},{"month":5,"riseRate":0,"avgChangeRate":-0.04895},{"month":6,"riseRate":0.6,"avgChangeRate":-0.022081},{"month":7,"riseRate":0.4,"avgChangeRate":0.012049},{"month":8,"riseRate":0.4,"avgChangeRate":0.000462},{"month":9,"riseRate":0.75,"avgChangeRate":-0.018319},{"month":10,"riseRate":0.5,"avgChangeRate":0.000568},{"month":11,"riseRate":0.5,"avgChangeRate":0.013756},{"month":12,"riseRate":0.75,"avgChangeRate":0.195702}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV","nameEN":"NEWAMSTERDAM PHARMA CO NV"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供NEWAMSTERDAM PHARMA CO NV(NAMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"NEWAMSTERDAM PHARMA CO NV,NAMS,NEWAMSTERDAM PHARMA CO NV股票,NEWAMSTERDAM PHARMA CO NV股票老虎,NEWAMSTERDAM PHARMA CO NV股票老虎国际,NEWAMSTERDAM PHARMA CO NV行情,NEWAMSTERDAM PHARMA CO NV股票行情,NEWAMSTERDAM PHARMA CO NV股价,NEWAMSTERDAM PHARMA CO NV股市,NEWAMSTERDAM PHARMA CO NV股票价格,NEWAMSTERDAM PHARMA CO NV股票交易,NEWAMSTERDAM PHARMA CO NV股票购买,NEWAMSTERDAM PHARMA CO NV股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NEWAMSTERDAM PHARMA CO NV(NAMS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供NEWAMSTERDAM PHARMA CO NV(NAMS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}